These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17139361)

  • 1. PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy.
    Schalkwijk CG; Stehouwer CD
    Thromb Haemost; 2006 Dec; 96(6):698-9. PubMed ID: 17139361
    [No Abstract]   [Full Text] [Related]  

  • 2. Tiplaxtinin impairs nutritionally induced obesity in mice.
    Lijnen HR; Alessi MC; Frederix L; Collen D; Juhan-Vague I
    Thromb Haemost; 2006 Dec; 96(6):731-7. PubMed ID: 17139366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1.
    Skurk T; Hauner H
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1357-64. PubMed ID: 15356668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors.
    Brown NJ
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):315-24. PubMed ID: 20660535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modulation of tissue exposure to cortisol, new perspective for reducing the metabolic risk associated with obesity].
    Iovino A; Scheen AJ
    Rev Med Liege; 2010 Mar; 65(3):140-6. PubMed ID: 20411818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tongqiaohuoxue decoction ameliorates obesity-induced inflammation and the prothrombotic state by regulating adiponectin and plasminogen activator inhibitor-1.
    Kim SH; Park HS; Hong MJ; Yoo JY; Lee H; Lee JA; Hur J; Kwon DY; Kim MS
    J Ethnopharmacol; 2016 Nov; 192():201-209. PubMed ID: 27404230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome.
    Poekes L; Lanthier N; Leclercq IA
    Clin Sci (Lond); 2015 Dec; 129(11):933-49. PubMed ID: 26359253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.
    Maynadier M; Basile I; Gary-Bobo M
    Drug Discov Today; 2009 Feb; 14(3-4):192-7. PubMed ID: 18951999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of proteolysis in development of murine adipose tissue.
    Christiaens V; Scroyen I; Lijnen HR
    Thromb Haemost; 2008 Feb; 99(2):290-4. PubMed ID: 18278177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance.
    Alessi MC; Poggi M; Juhan-Vague I
    Curr Opin Lipidol; 2007 Jun; 18(3):240-5. PubMed ID: 17495595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome.
    Nisoli E; Carruba MO
    Pharmacol Res; 2004 Nov; 50(5):453-69. PubMed ID: 15458765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 and haemostasis in obesity.
    Mutch NJ; Wilson HM; Booth NA
    Proc Nutr Soc; 2001 Aug; 60(3):341-7. PubMed ID: 11681808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAI-1 and the metabolic syndrome: links, causes, and consequences.
    Alessi MC; Juhan-Vague I
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2200-7. PubMed ID: 16931789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight change and blood coagulability and fibrinolysis in healthy obese women.
    Rissanen P; Vahtera E; Krusius T; Uusitupa M; Rissanen A
    Int J Obes Relat Metab Disord; 2001 Feb; 25(2):212-8. PubMed ID: 11410822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 in aging.
    Yamamoto K; Takeshita K; Saito H
    Semin Thromb Hemost; 2014 Sep; 40(6):652-9. PubMed ID: 25122500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral fat as a determinant of fibrinolysis and hemostasis.
    Mertens I; Van Gaal LF
    Semin Vasc Med; 2005 Feb; 5(1):48-55. PubMed ID: 15968580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
    Alessi MC; Bastelica D; Mavri A; Morange P; Berthet B; Grino M; Juhan-Vague I
    Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1262-8. PubMed ID: 12750120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
    Appel SJ; Harrell JS; Davenport ML
    J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of adipose tissue development by pharmacological inhibition of PAI-1.
    Crandall DL; Quinet EM; El Ayachi S; Hreha AL; Leik CE; Savio DA; Juhan-Vague I; Alessi MC
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2209-15. PubMed ID: 16825598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors.
    You T; Yang R; Lyles MF; Gong D; Nicklas BJ
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E741-7. PubMed ID: 15562250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.